Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Toxins01:36

Types of Toxins

3.6K
Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
3.6K
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

4.1K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
4.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

379
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
379
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

151
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
151
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

200
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
200

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A latching magnetooptical polarization switch.

Applied optics·2010
Same author

EXAFS study of uranyl nitrate dimer at high and low temperature.

Inorganic chemistry·2001
Same author

Tungsten fluorides: syntheses and electrochemical characterization in the FLINAK molten salt eutectic.

Inorganic chemistry·2001
Same author

Is an integrated practice in your future?

The Internist·1995
Same author

Teaching human anatomy in physical therapy education in the United States: a survey.

Physical therapy·1994
Same author

Complications associated with the Seidel nail.

Orthopaedic review·1993
Same journal

Encore! Encore!

Physician executive·2014
Same journal

The medical loss ratio: a core component of reform.

Physician executive·2014
Same journal

Avoid the breach: put data security measures in place.

Physician executive·2014
Same journal

Hospitals of excellence and geography: an update.

Physician executive·2014
Same journal

Collegial intervention and the disruptive physician.

Physician executive·2014
Same journal

Standardizing electronic medical record documentation.

Physician executive·2014
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
08:39

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

7.7K

Quality improvement act gets first antitrust test.

C E Barnes

    Physician Executive
    |June 8, 1990
    PubMed
    Summary
    This summary is machine-generated.

    The Health Care Quality Improvement Act of 1986 protected a hospital and physicians from antitrust claims regarding staff privileges. This case was the first to affirm these immunity protections for such claims.

    More Related Videos

    Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction
    09:15

    Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction

    Published on: January 12, 2020

    7.0K
    Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
    08:25

    Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

    Published on: June 5, 2020

    6.7K

    Related Experiment Videos

    Last Updated: Apr 26, 2026

    Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
    08:39

    Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

    Published on: September 16, 2020

    7.7K
    Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction
    09:15

    Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction

    Published on: January 12, 2020

    7.0K
    Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
    08:25

    Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

    Published on: June 5, 2020

    6.7K

    Area of Science:

    • Health Law
    • Antitrust Law
    • Medical Staff Privileges

    Background:

    • Dr. George M. Austin alleged a conspiracy by Santa Barbara Cottage Hospital and physicians to suspend his privileges.
    • The claim cited a violation of Section 1 of the Sherman Act, a federal antitrust law.

    Purpose of the Study:

    • To analyze the application of the Health Care Quality Improvement Act of 1986 to staff privileges disputes.
    • To determine the extent of immunity granted by the Act against antitrust claims in the healthcare sector.

    Main Methods:

    • Legal analysis of a Federal District Court opinion.
    • Examination of the court's application of the Health Care Quality Improvement Act of 1986.

    Main Results:

    • The court dismissed Dr. Austin's antitrust claim, finding the hospital and physicians immune.
    • This decision marked the first affirmation of the Act's immunity protections for staff privileges claims.

    Conclusions:

    • The Health Care Quality Improvement Act of 1986 provides significant immunity for healthcare providers facing antitrust challenges related to peer review and staff privileges.
    • This ruling sets a precedent for future cases involving similar disputes under federal antitrust laws.